ArticleCureus2025
Investigating the Increasing Azole Resistance in Candida Infections Among Critically Ill Patients: Experience From a Tertiary-Level Setup in North India.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Article
- Analysis of the genome of a Pseudomonas monsensis isolate that produces the antifungal dipeptide maculosin.Access microbiology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionCandida species are among the most common fungal pathogens worldwide, with varied clinical presentations and manifestations in both immunocompetent and compromised individuals. In recent years, both global and Indian research have documented a progressive shift from
objectivesThe present study aims to identify the spectrum of Candida species in clinical infections and to identify their sensitivity pattern to available antifungal agents.
methodsThe study was conducted over 24 months, from April 2023 to March 2025, on clinical samples received for routine culture and sensitivity testing. Antifungal sensitivity was tested according to the Clinical and Laboratory Standards Institute guidelines and interpreted. Demographic and other patient parameters were also assessed. STATISTICAL ANALYSIS: The results were analyzed using the Statistical Package for the Social Sciences version 22 software (SPSS Inc., Chicago, IL).
resultsThe total number of samples analyzed for fungal etiology during the specified time period was 382, of which 57.5% (n = 219) were contributed by blood, 29.2% (n = 112) by urine samples, and the remaining 13.3% (n = 51) by intra-abdominal samples, tissue, pus, and body fluids. Individually,
conclusionOur study emphasizes the role of increased Candida isolates and resistance trends across various samples over the specified time period.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.